Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Slides:

Advertisements

Similar presentations

RAS PI3’K AKT RAL-GEF U0126 PD98059 PD (CI-1040) proliferation survival proliferation / differentiation survival migration proliferation RAF MEK.

Advertisements

v SCF Ras GDP Inactive nucleus SCF Ras GDP Inactive nucleus.

Insulin Signaling – Insulin Resistance Elmus G. Beale, Professor Texas Tech University Health Sciences Center Paul L. Foster School of Medicine PhD, Baylor.

Growth Factors, Receptors, and Signal Transduction II

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Breast Cancer slide presentation is not an independent educational.

Ligand Receptor Cortisol Receptor is located in the cytosol Retinoid Receptors are in the nucleus Target gene in the nucleus Regulation of Transcription.

Modeling of Acute Resistance to the HER2 Inhibitor, Lapatinib, in Breast Cancer Cells Marc Fink & Yan Liu Student Project Proposal Computational Cell Biology.

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.

ER signalling in HER2-positive breast cancer 18th Annual Perspectives in Breast Cancer New York, August 18th 2011 Ruth M. O’Regan, MD Professor and Vice-Chair.

Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg) Louis M. Weiner, MD Lombardi Comprehensive Cancer Center Georgetown.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Ρύθμιση κυτταρικού κύκλου & Εισαγωγή στην κυτταρική σηματοδότηση Γιώργος Ρασιδάκης Επ. Καθηγητής Παθολογικής Ανατομικής, Ιατρική Σχολή ΕΚΠΑ Adj. Assistant.

1 Hepatocellular Carcinoma Overview of Hepatocellular Carcinoma Epidemiology.

Growth Factors, Receptors,

How to present a scientific paper Dr. Rebecca B. Riggins Department of Oncology, Georgetown University

Specialized signaling pathways 1: RTK associated pathways

Marc Fink & Yan Liu & Shangying Wang Student Project Proposal

Extracellular Environment. Extracellular Environment.

Bio 714 Foster TGF-beta/cell cycle material. Points: Suppression of either PLD or mTOR in the absence of serum results in apoptosis Importantly, suppression.

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

Negative regulation of cell cycle by intracellular signals Checkpoint p53 detects DNA damage & activates p21 p21 inhibits cdk2-cyclinA Intracellular Regulation.

PHL 616 Drug Discovery & Development Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:

Marc Fink & Yan Liu & Shangying Wang Student Project Proposal

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Article title: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells Journal: Breast Cancer Research and.

سرطان الثدي Breast Cancer

Underlying Mechanisms for Distant Metastasis - Molecular Biology

MAPK pathway inhibitors.

Miriam Marqués, Francisco X. Real European Urology

BRAF inhibitor: targeted therapy in hairy cell leukemia

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

Figure 4 Possible combination therapies CDK4/6 inhibitors

The Akt-mTOR tango and its relevance to cancer

Figure 1 A schematic representation of the HER2 signalling pathway

Kinase inhibitors: Vice becomes virtue

mTORC1: Turning Off Is Just as Important as Turning On

Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic.

Targeted Therapies in Melanoma: Translational Research at Its Finest

Volume 29, Issue 3, Pages (March 2016)

The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Rapamycin: One Drug, Many Effects

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Nat. Rev. Urol. doi: /nrurol

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

How to present a scientific paper

The RAF Inhibitor Paradox Revisited

The RAS/MAPK Axis Gets Stressed Out

NOTCH and PI3K-AKT Pathways Intertwined

AKT/PKB Signaling: Navigating Downstream

Rapamycin: One Drug, Many Effects

mTOR and Akt Signaling in Cancer: SGK Cycles In

Platelet-derived growth factor (PDGF) signalling pathway.

BC Basics 2017.

Mutant BRAF Melanomas—Dependence and Resistance

Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer Sarah B. Crist, Cyrus M.

Brief Review – Growth Factors and Receptors

Simplified BRAF signaling network.

Changes in signal transduction pathway induced by gefitinib.

Combined inhibition of coamplified RTKs is required for response.

Successful targeting of ErbB2 receptors—is PTEN the key?

Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

AXL is not necessary for maintenance of intrinsic resistance.

Presentation transcript:

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post

HER2 and Breast Cancer Amplification or chromosomal region 17q12 RTK of the EGFR-family HER2 is overexpressed and induces a state in which proliferation and survival are increased Several drugs are approved for molecularly tailored treatment (trastuzumab and lapatinib) They often induce resistance after 1-2 years of treatment

HER2 Signaling HER2 P P PI3K AKT Grb2 Shc SOS Ras TSC2 TSC1 Raf MEK 1/2 ERK 1/2 RSK mTORC 1 p70S6k S6 Rheb * * * P P IGF1R P P FGFR What are the intracellular targets that may be useful for targeting HER2-breast cancers? How does the network reorganize after HER2 inhibition?